![](https://endpts.com/wp-content/uploads/2021/03/Robert-Bradway-Getty-1-scaled.jpg)
Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)
Amgen takes a swing at regenerative immunology with $721M acquisition of Rodeo Therapeutics
With blockbuster immunology meds Enbrel and Otezla already in the fold, Amgen has mostly stood pat on infusing new blood into its legacy pipeline. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.